| View |
|
BR-469
|
Human Serum Immunoglobulin
|
I.V. - Globulin SN Injection
|
50 mg/mL (2,500 mg/50 mL)
|
Solution for Injection (IV)
|
-
|
Green Cross Corp.
|
Korea
|
-
|
26 February 2021
|
06 September 2025
|
| View |
|
BR-470
|
Live Attenuated Measles Vaccine
|
None
|
Multidose
|
Freeze-Dried Powder For Injection (Multidose) (SC)
|
-
|
Serum Institute of India Private Limited
|
India
|
-
|
08 March 2021
|
14 December 2025
|
| View |
|
BR-471
|
Tetanus Toxoid ( Adsorbed )
|
None
|
40IU/0.5mL
|
Suspension For Injection (IM) (Multidose)
|
-
|
Serum Institue of India Private Limited
|
India
|
-
|
18 March 2022
|
30 August 2026
|
| View |
|
BR-488
|
Human Albumin
|
Zenalb-20
|
0.2
|
Solution For Injection (IV)
|
-
|
Bio Products Laboratory Limited
|
United
Kingdom
|
-
|
27 April 2022
|
03 March 2026
|
| View |
|
BR-494
|
Human Albumin
|
Albutein 20%
|
20%
|
Solution for IV Infusion
|
-
|
Grifols Biologicals LLC
|
U.S.A.
|
-
|
18 May 2021
|
25 April 2025
|
| View |
|
BR-498
|
Inactivated Poliomyelitis Vaccine (Type 1,2 And 3)
|
Imovax Polio
|
Formulation: One dose (0.5 mL) contains: Poliovirus type 1, Mahoney strain (inactivated)-40 D-antigen Units Poliovirus type 2, MFF-I strain (inactivated)- 8 D-antigen Units Poliovirus type 3, Saukett strain (inactivated) - 32 D-antigen Units
|
Suspension For Injection (IM/SC)
|
-
|
Sanofi Pasteur
|
France
|
Renewal
|
05 May 2022
|
21 May 2027
|
| View |
|
BR-500
|
Hepatitis B Vaccine (rdna)
|
Hepliv
|
20mcg/mL
|
Suspension for IM Injection
|
Vaccine
|
Bharat Biotech International Ltd.
|
India
|
Automatic Renewal
|
19 October 2021
|
09 October 2026
|
| View |
|
BR-501
|
Hepatitis B Vaccine (rdna)
|
Hepliv
|
20mcg/ mL
|
Suspension for IM Injection
|
Vaccine
|
Bharat Biotech International Ltd.
|
India
|
Automatic Renewal
|
13 October 2021
|
09 October 2026
|
| View |
|
BR-502
|
Hepatitis B Vaccine (rdna)
|
Hepliv
|
100mcg/ 0.5mL
|
Suspension for IM Injection
|
Vaccine
|
Bharat Biotech International Ltd.
|
India
|
Automatic Renewal
|
13 October 2021
|
09 October 2026
|
| View |
|
BR-508
|
Diphtheria, Tetanus and Pertussis (acellular
component), Hepatitis B (rDNA), Poliomyelitis (inactivated) and Haemophilus influenzae Type B
Conjugate Vaccine (adsorbed)
|
Infanrix Hexa
|
|
Suspension for Injection (IM) (Preservative-free)
|
-
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
-
|
27 November 2020
|
11 February 2025
|
| View |
|
BR-513
|
Hepatitis A Vaccine (Inactivated, Adsorbed)
|
Avaxim 80
|
Formulation:
Each dose (0.5 mL) contains:
Hepatitis A virus, GBM Strain* (inactivated)** 80 ELISA units***
*Cultured on MRC-5 human diploid cells
** Adsorbed on hydrated aluminum hydroxide (0.15 mg of Al3)
*** In the absence of an international standardised reference, the antigen content is expressed using an in-house reference
|
Suspension for Injection (IM)
|
-
|
Sanofi Pasteur
|
France
|
Renewal
|
30 January 2023
|
05 December 2027
|
| View |
|
BR-514
|
Rabies Vaccine (Inactivated) (Wistar Strain Rabies)
|
Verorab
|
2.5 IU/ 0.5 mL
|
Powder for Suspension for Injection
(ID/IM)
|
-
|
Sanofi Pasteur SA
|
France
|
Renewal
|
03 July 2023
|
10 December 2027
|
| View |
|
BR-515
|
Rabies Vaccine (Inactivated)
|
Chirorab
|
2.5 I.U./mL
|
Lyophilized Powder for Injection (ID/IM)
|
Vaccines
|
Chiron Behring Vaccines Pvt., Ltd.
|
India
|
Renewal (Reconstruction)
|
27 February 2023
|
25 January 2026
|
| View |
|
BR-518
|
Diphtheria, Tetanus, Pertussis (Acellular Component), And Poliomyelitis (Inactivated) Vaccine (Adsorbed)
|
Tetraxim
|
MULTICOMPONENT/0.5ML
|
Suspension For Injection (IM)
|
-
|
Sanofi Pasteur
|
France
|
Initial (Variation)
|
10 November 2022
|
10 November 2027
|
| View |
|
BR-523
|
Diphtheria, Tetanus, Pertussis (Acellular Poliomyelitis (Inactivated) Vaccine and Haemophilus influenzae Type B Conjugate Vaccine (Adsorbed)
|
Pentaxim
|
After reconstitution, each dose (0.5 mL) contains:
Diphtheria toxoid
Tetanus toxoid
Bordetella pertussis antigen
Pertussis toxoid
Filamentous hemagglutinin Poliovirus (Inactivated)
>30 IU
>40 IU
Polysaccharide influenzae Type B Conjugated to tetanus protein
of
Haemophilus 10 mcg
18-30 mcg
25 mcg
25 mcg
Type I poliomyelitis virus (inactivated)
40 D antigen
units
Type II poliomyelitis virus (inactivated)
8 D antigen units
Type III poliomyelitis virus (inactivated)
32
D' antigen
|
Suspension and Powder for Suspension for Injection (IM)
|
-
|
Sanofi Pasteur, Inc.
|
France
|
Renewal
|
14 September 2023
|
21 August 2028
|
| View |
|
BR-525
|
Tetanus Antitoxin Refined
|
Antitet 1500 Iu
|
1500 IU 0.7mL
|
Solution For Injection
|
Antisera
|
Jiangxi Institute of Biological Products
|
China
|
Automatic Renewal
|
08 July 2023
|
09 June 2028
|
| View |
|
BR-526
|
Tetanus Antitoxin Refined
|
Antitet 5000 Iu
|
5000 IU/2mL
|
Solution For Injection
|
Antisera
|
Jiangxi Institute of Biological Products
|
China
|
Automatic Renewal
|
08 July 2023
|
09 June 2028
|
| View |
|
BR-527
|
Tetanus Antitoxin Refined
|
Antitet 3000 Iu
|
3000 I.U./0.95%
|
Solution For Injection
|
Antisera
|
Jiangxi Institute of Biological Products
|
China
|
Automatic Renewal
|
08 July 2023
|
19 June 2028
|
| View |
|
BR-531
|
Human Albumin
|
Albutein
|
0.05
|
Solution for Injection for Infusion (IV)
|
-
|
Grifols Biologicals LLC
|
U.S.A
|
Renewal
|
28 April 2023
|
25 May 2027
|
| View |
|
BR-536
|
Human Plasma Coagulation Factor VIII
|
Emoclot
|
500 IU
|
Lyophilized Powder for Injection (IV)
|
-
|
Kedrion S.p.A
|
Italy
|
Initial (Variation)
|
06 October 2022
|
06 October 2027
|